Figure 2
Mass spectrometric analysis of the HLA-presented peptidome of MM.1S cell under carfilzomib treatment. (a) HLA class I ligand extracts of MM.1S cells before in vitro treatment and 24 h/48 h (t24h, t48h) after a 1-h pulse with 100 nm carfilzomib (Carfilzomib) or 5% glucose (Mock) were analyzed in biological triplicates using sample shares of 20% in dose-finding mass spectrometry runs. The raw number of HLA ligand identifications and the summed area under the curves (AUC) of their extracted ion chromatograms are indicated in gray and black bars, respectively. (b) Numbers of peptide identifications after adjustment of the injected sample amounts. The sample amounts were adjusted according to their ratios of summed AUC and each condition was analyzed in five technical replicates, allowing for LFQ of the relative peptide abundances. (c) Overlap of the 1908 different HLA class I ligands identified on MM.1S cells compared with a set of 197 different myeloma-associated peptides described in an earlier study.18
